Evidence map›Paper›PMID 35807304›Full record

ArticleMolecules (Basel, Switzerland)2022

How Curcumin Targets Inflammatory Mediators in Diabetes: Therapeutic Insights and Possible Solutions.

Yaseen Hussain, Haroon Khan, Ghallab Alotaibi, Fazlullah Khan, Waqas Alam, Michael Aschner, Philippe Jeandet, Luciano Saso

Open access · goldAbstract read
In one paragraph

Article in Molecules (Basel, Switzerland), 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 28 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
28citing papers in PubMed, 2 pooled it
4.1field-weighted citation impact, top 4% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

28 citing papers in PubMed, 2 syntheses or guidelines pooled it, 59 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Review
  4. Article
  5. Article
  6. Review
  7. Article
  8. Article
  9. Review
  10. Review
  11. Article
  12. Review
  13. Article
  14. Article
  15. Article
  16. Preclinical Evidence ofBiomedicines · 2025
    Review
  17. Review
  18. Article
  19. Review
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 7 institutions in 6 countries.

Yaseen HussainCollege of Pharmaceutical Sciences, Soochow University, Suzhou 215123, China.ORCID 0000-0003-1054-6720
Haroon KhanDepartment of Pharmacy, Abdul Wali Khan University Mardan, Mardan 23200, Pakistan.
Ghallab AlotaibiDepartment of Pharmaceutical Sciences, Al-Dawadmi Campus, College of Pharmacy, Shaqra University, Riyadh 11961, Saudi Arabia.
Fazlullah KhanFaculty of Pharmacy, Capital University of Science & Technology, Islamabad 44000, Pakistan.ORCID 0000-0003-2473-6090
Waqas AlamDepartment of Pharmacy, Abdul Wali Khan University Mardan, Mardan 23200, Pakistan.ORCID 0000-0001-8329-9180
Michael AschnerDepartment of Molecular Pharmacology, Albert Einstein College of Medicine, Bronx, NY 10461, USA.ORCID 0000-0002-2619-1656
Philippe JeandetResearch Unit "Induced Resistance and Plant Bioprotection", Department of Biology and Biochemistry, Faculty of Sciences, University of Reims, EA 4707-USC INRAe 1488, SFR Condorcet FR CNRS 3417, P.O. Box 1039, CEDEX 02, 51687 Reims, France.ORCID 0000-0003-3023-4871
Luciano SasoDepartment of Physiology and Pharmacology "Vittorio Erspamer", Sapienza University, Piazzale Aldo Moro 5, 00185 Rome, Italy.ORCID 0000-0003-4530-8706
Abdul Wali Khan University Mardan · PKAlbert Einstein College of Medicine · USCapital University of Science and Technology · PKCentre National de la Recherche Scientifique · FRSapienza University of Rome · ITShaqra University · SASoochow University · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Diabetes mellitus is a multifactorial chronic metabolic disorder, characterized by altered metabolism of macro-nutrients, such as fats, proteins, and carbohydrates. Diabetic retinopathy, diabetic cardiomyopathy, diabetic encephalopathy, diabetic periodontitis, and diabetic nephropathy are the prominent complications of diabetes. Inflammatory mediators are primarily responsible for these complications. Curcumin, a polyphenol derived from turmeric, is well known for its anti-oxidant, anti-inflammatory, and anti-apoptotic properties. The regulation of several signaling pathways effectively targets inflammatory mediators in diabetes. Curcumin's anti-inflammatory and anti-oxidative activities against a wide range of molecular targets have been shown to have therapeutic potential for a variety of chronic inflammatory disorders, including diabetes. Curcumin's biological examination has shown that it is a powerful anti-oxidant that stops cells from growing by releasing active free thiol groups at the target location. Curcumin is a powerful anti-inflammatory agent that targets inflammatory mediators in diabetes, and its resistant form leads to better therapeutic outcomes in diabetes complications. Moreover, Curcumin is an anti-oxidant and NF-B inhibitor that may be useful in treating diabetes. Curcumin has been shown to inhibit diabetes-related enzymes, such as a-glucosidase, aldose reductase and aldose reductase inhibitors. Through its anti-oxidant and anti-inflammatory effects, and its suppression of vascular endothelial development and nuclear transcription factors, curcumin has the ability to prevent, or reduce, the course of diabetic retinopathy. Curcumin improves insulin sensitivity by suppressing phosphorylation of ERK/JNK in HG-induced insulin-resistant cells and strengthening the PI3K-AKT-GSK3B signaling pathway. In the present article, we aimed to discuss the anti-inflammatory mechanisms of curcumin in diabetes regulated by various molecular signaling pathways.

Indexed as

CurcuminDiabetes MellitusDiabetic NephropathiesAldehyde ReductaseAnti-Inflammatory AgentsAntioxidantsHumansInflammation MediatorsPhosphatidylinositol 3-KinasesAldehyde ReductaseAnti-Inflammatory AgentsAntioxidantsCurcuminInflammation MediatorsPhosphatidylinositol 3-Kinasescurcumindiabetes mellitusdiabetes resistanceinflammatory mediatorslate complications

Identifiers

PMID35807304
PMCPMC9268477
OpenAlexW4283577406

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.